This article is more than 5 years old. Information may no longer be current.

Pivotal ROP trials to use retinal imaging camera

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PLEASANTON, Calif. — Two clinical trials centered around the use of anti-VEGF therapy for the treatment of retinopathy of prematurity will employ the RetCam Digital Imaging System, the manufacturer of the device announced in a press release.

The BLOCK-ROP (Pan-VEGF blockade for the treatment of retinopathy of prematurity) trial will investigate the safety of a single dose of Avastin (bevacizumab, Genetech) and its efficacy in improving the retinal architecture in patients who have failed prior laser therapy.

The BEAT-ROP (Bevacizumab eliminates the angiogenic threat of retinopathy of prematurity) trial will look at whether bevacizumab reduces the neovascularization component compared with a conventional laser therapy control group.

Both trials, which are currently enrolling patients, will use the RetCam (Clarity Medical Systems), which is touted as the only ophthalmic camera specifically designed for imaging infants and small children. Use of the objective measuring device should further help clarify results of the two trials, investigators said.